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Background: More than 100 surgical approaches to treat rectal prolapse have been described. These can be done
through the perineum or transabdominally. Delorme’s procedure is the most frequently used perineal, resection
rectopexy the most commonly used abdominal procedure. Recurrences seem more common after perineal
compared to abdominal techniques, but the latter may carry a higher risk of peri- and postoperative morbidity and
mortality.
Methods/Design: DeloRes is a randomized, controlled, observer-blinded multicenter trial with two parallel groups.
Patients with a full-thickness rectal prolapse (third degree prolapse), considered eligible for both operative methods
are included. The primary outcome is time to recurrence of full-thickness rectal prolapse during the 24 months
following primary surgery. Secondary endpoints are time to and incidence of recurrence of full-thickness rectal
prolapse during the 5-year follow-up, duration of surgery, morbidity, hospital stay, quality of life, constipation, and
fecal incontinence. A meta-analysis was done on the basis of the available data on recurrence rates from 17
publications comprising 1,140 patients. Based on the results of a meta-analysis it is assumed that the recurrence
rate after 2 years is 20% for Delorme’s procedure and 5% for resection rectopexy. Considering a rate of lost to
follow-up without recurrence of 30% a total of 130 patients (2 x 65 patients) was calculated as an adequate sample
size to assure a power of 80% for the confirmatory analysis.
Discussion: The DeloRes Trial will clarify which procedure results in a smaller recurrence rate but also give
information on how morbidity and functional results compare.
Trial registration: German Clinical Trial Number DRKS00000482
Keywords: Rectal prolapse, Surgery, Delorme’s procedure, Resection rectopexy, RecurrenceBackground
Full-thickness prolapse of the rectum is defined as pro-
trusion of the full thickness of the rectal wall through
the anus. There is a peak in the incidence of this disease
in the seventh decade of life. A total of 80% to 95% of
the patients are women [1,2]. The etiology of rectal* Correspondence: Stefan.post@umm.de
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distribution, and reproduction in any mediumprolapse is still unknown. Fifty percent to seventy
percent of patients complain of longstanding constipa-
tion, the rate of fecal incontinence ranges between 40%
and 80% [3-6]. Other predisposing conditions include
chronic straining defecation, pregnancy, previous sur-
gery, and neurological disease. There is probably a
genetic disposition to this condition.
Treatment of rectal prolapse is usually surgical. More
than 100 surgical approaches have been described in the lit-
erature. The aims of the operation are to correct the rectal
prolapse, to restore normal bowel function, and to avoid aentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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patients, constipation and fecal incontinence improve after
surgery [4,7,8].
Basically, two different surgical approaches can be
distinguished: perineal and transabdominal proce-
dures. In general, perineal surgical repairs supposedly
cause less morbidity and mortality compared with
abdominal operations [7,9,10]. They are considered
especially indicated in the elderly and/or high-risk
patients as they can also be done in spinal or epi-
dural anesthesia [9,11,12]. On the other hand, recur-
rences seem more frequent after perineal techniques
than after abdominal operations [1-3,13]. Abdominal
repairs involve fixing the rectum to the sacrum by
using either mesh or sutures. In addition to rectopexy
a sigmoid resection is commonly performed. Laparo-
scopic repair of rectal prolapse has similar morbidity
and recurrence rates as open surgery [7,14]. There
are data suggesting that the laparoscopic compared to
the conventional approach has short-term benefits as
described for other laparoscopic abdominal proce-
dures (reduced length of hospital stay, less postopera-
tive pain, faster return to normal bowel function, and
less wound complications) [9,15]. But when using a
modern fast-track regime (involving multimodal
balanced anesthesia and analgesia including peridural
catheter, early normal nutrition and mobilization as
well as avoidance of tubes and catheters) the advan-
tages of a laparoscopic approach have become some-
what less clear [15-17]. In general the fast-track
regime allows enhanced recovery and discharge of
patients compared to conventional postoperative
management. Application of such a fast-track regime
allows compensation of assumed disadvantages like
more pain or slower mobilization of patients after
open abdominal surgery compared to laparoscopic
surgery.
In conclusion, perineal as well as abdominal (mostly
laparoscopic) procedures remain the established options
in the surgical treatment of rectal prolapse without evi-
dence from adequately designed randomized studies
which of these procedures are superior. There are only
insufficient data available on the long-term benefits and
risks, quality of life, and total treatment costs. Our trial
aims to contribute to the very scarce high-level-evidence
basis of randomized trials comparing a perineal vs. an
abdominal approach. The urgent need for a randomized
trial such as DeloRes was also pointed out in the
Cochrane Review by Tou in 2009 [18].
Methods/Design
Trial design
DeloRes is a randomized, controlled, observer-blinded
multicenter trial with two parallel groups.Patient population
Inclusion criteria
 Full-thickness rectal prolapse, externally visible on
straining
 ASA-Score I-III
 Patient is suited for both standardized surgical
approaches
 Patient is able to cooperate
 Patient has given written informed consent
 Aged 18 years or older
Exclusion criteria
 Recurrence of full-thickness rectal prolapse
 Patient with stoma
 Patient with inflammatory bowel disease
 Pregnancy or breastfeeding
 Patient currently under chemotherapy
 Active malignant disease and life expectancy less
than 24 months
 Body mass index greater than 40
 Participation in another intervention trial with
interference of intervention and outcome of this
study
The aim was to exclude as few patients as possible,
but nevertheless minimize attrition bias in long-term fol-
low-up and enable a high recruitment rate given the fact
that patients presenting with full rectal prolapse are a
small population of a reasonably higher population of
patients not willing to present at their physicians be-
cause of misinformation or shame.
Thus patients with recurrent rectal prolapse would
often not be acceptable for surgeons to be randomized
to perineal vs. abdominal approach especially if the prior
surgery had been a perineal approach. Patients not sur-
viving at least 24 months would not be available for the
primary endpoint visit at 24 months postoperatively.
And patients with BMI > 40 had been excluded as they
are very few and do not represent the common patient
habitus of rectal prolapse.
Scheme of intervention
DeloRes will be performed in 13 trial centers. All partici-
pating centers are cooperating units with a special focus
on colorectal surgery and all centers perform between
eight and sixty surgical interventions for rectal prolapse
per year. In order to minimize performance bias, only
surgeons with an adequate experience in performing the
approaches investigated operate on patients in this study
(minimum number of procedures performed (‘life-time
experience’): Delorme’s procedure=20, (laparoscopic)
resection rectopexy=20). Each study center provides at
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Delorme’s procedure and one surgeon with the required
experience for (laparoscopic) resection rectopexy (expert-
ise based, best team approach). To ensure standardization
for all participating centers an operative manual with stan-
dardized video sequences will be prepared. Moreover,
consented crucial steps of each procedure will be captured
in the clinical record file. In addition, in order to allow
confirmation of a certain procedure quality, selected
digital photos will be taken.
To reflect current practice and to increase external
validity of the trial, perioperative standards (for example,
bowel preparation, parenteral nutrition, fast-track, post-
operative application of laxatives) will not be strictly
standardized. Each trial center, however, will document
its own standards in a short questionnaire and agrees
not to change this standard during trial recruitment.
Recruitment and trial timeline
Recruitment of participants started in September 2010.
The duration of the trial for each patient is expected to
be 60 months with follow-up at 6, 12, 24, and 60 months
after the primary surgery.
Treatment assignment and randomization
Consecutively screened and eligible patients will be
included in the trial. In order to achieve comparable
intervention groups, patients will be allocated by pre-
operative randomization 24 to 48 h prior to surgery after
given written informed consent using a centralized web
based tool (www.randomizer.at). Block randomization
stratified by center will be applied to achieve equal
group sizes per center.
Interventions and trial flow
The laparoscopic approach is considered the standard ap-
proach for the transabdominal operation of full-thickness
rectal prolapse. Laparoscopic resection rectopexy is sug-
gested to yield better results in the early postoperative
phase in comparison to the open approaches with equal
recurrence rates in comparison to the open approach.
However, the advantages of a laparoscopic approach be-
come somewhat less evident under a fast-track regime,
therefore open resection rectopexy is also acceptable via a
Pfannenstiel incision. The latter approach has proven to
be only moderately invasive in numerous procedures of
the lower abdomen. The most frequently used perineal
procedure is Delorme’s procedure, which shows low
postoperative morbidity. The trial flow is illustrated in
Figure 1.
Description of trial days
All patients will be informed about the purpose of the
trial and surgical treatment modalities comprising theirbenefits as well as risks. The schedule of trial interven-
tions is presented in Table 1.
Outcome measures and definitions
The clinically most relevant parameter in the treatment
of full-thickness rectal prolapse is the time to recur-
rence. Therefore this parameter is defined as primary
outcome measure, evaluated during the 24 months fol-
lowing primary surgery. Recurrence is defined as the cir-
cular protrusion of rectal mucosa through the anal canal
and will be examined by standardized history, clinical
examination, and photo documentation. To assess the
primary outcome, patients are asked to perform a strain-
ing maneuver in a sitting position (patients not able to
sit will be assessed in a lateral decubitus position). Then
a photograph is taken during straining. The primary out-
come is finally determined by the independent review
board on the basis of the photograph.
Secondary endpoints are time to and incidence of re-
currence of full-thickness rectal prolapse during 5-year
follow-up, duration of surgical intervention, morbidity,
SAE, all causes of mortality within 3 months after
primary surgery (this period was chosen to get any mor-
tality possible related to surgery. Patients with rectal
prolapse are usually rather old and frail. There are mul-
tiple reasons for further morbidity or mortality which
are expected to be unrelated to the surgical procedure in
case they occur beyond the first 3 months), length of ini-
tial hospital stay, reoperation rate for recurrent prolapse,
cumulative hospital stay and change in quality of life,
constipation, and fecal incontinence as measured by
appropriate questionnaires.
The time to and the incidence of recurrence of full-
thickness rectal prolapse during a 5-year follow-up after
primary surgery will be assessed as explained above.
Morbidity occurring during the primary hospital stay is
further differentiated into surgical and non-surgical
complications, which are specifically defined as follow-
ing: severity grading is done with the Clavien classifica-
tion [19] and for anastomotic leakage with the
classification of the International Study Group of Rectal
Cancer [20]. The definitions of the secondary outcomes
are shown in Table 2.
Data management
All protocol-required information collected during the
trial must be documented in the paper-based CRF by
the investigator. Any outstanding entries must be com-
pleted immediately after the final examination. The
completed CRF must be reviewed and signed by the in-
vestigator named in the trial protocol.
In order to ensure that the database reproduces the
CRFs correctly a double entry of data will be performed
by two different people.
Figure 1 Trial flow/intervention scheme.
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Table 1 Study visits of DeloRes
Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 Visit 6 Visit 7


















× × × × × ×
Recurrence ×a ×a × ×
Secondary endpoints × × ×a ×a ×
SF-12 × ×a ×a ×
Herold
constipation score
× ×a ×a ×
Wexner score × ×a ×a ×
Rockwood-FIQLScore × ×a ×a ×
aIt is intended that patients come to the trial sites for all follow-up visits. If they are unable to travel they will be visited by a study nurse. At the 6- and 12-month
follow-up visits, recurrence status, secondary endpoints can exceptionally be assessed by phone interview and/or by mailing questionnaires.
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To reduce the number of patients not able or willing to
visit the study centers a study nurse will be appointed to
visit the patients and to assess the outcome at the speci-
fied time (‘flying study-nurse’). Furthermore, the time-
to-event method will be applied for the primary analysis
to allow for all available information including the obser-
vation time of patients who drop out early. Nevertheless,
an additional percentage of patients will be recruited to
assure a sufficient power for the confirmatory analysis.
Safety assessments and reporting of adverse events
Analysis of safety-related data is performed with respect
to frequency of serious adverse events, frequency of ser-
ious adverse events stratified by intensity and causality,
and frequency of morbidity in both treatment groups.
From the day of randomization until the regular end
of trial follow-up or until premature withdrawal of the
patient, all serious adverse events must be documented
on a ‘serious adverse event form’ available in the investi-
gator site file.
A serious adverse event will be defined as an event
that results in death, is immediately life-threatening,
requires or prolongs hospitalization beyond the 20th
postoperative day for any medical reason, requires re-
admission for any medical reason within 3 months after
the operation within this trial, requires readmission for
treatment of surgical complications related to the study
operation beyond 3 months postoperatively, or results in
persistent or significant disability or incapacity. Serious
adverse events will be classified in intensity (mild, mod-
erate, severe), outcome (recovered completely, recovered
with sequelae, not recovered, death, unknown), andcausality (unrelated, possibly related, probably related,
definitely related, not assessable).
The assessment is based on surgical findings and the
clinical course of the patient. It needs to be done by the
investigators. Serious adverse events have to be reported
by the attending physician to the coordinating investiga-
tor or one of both study supervisors within 24 h after
the SAE becomes known.
Statistical methods
Sample size calculation
The sample size calculation is based on the analysis of
the primary endpoint (time to recurrence of full-
thickness rectal prolapse during a 2-year follow-up).
A meta-analysis including 17 publications (Delorme
[2,5,6,8,9,12,13,25]; (Laparoscopic) Resection Rectopexy
[1,3,4,7,14,26-28]) showed recurrence rates ranging from
10% to 30% (Delorme’s procedure) and from 0% to 11%
(laparoscopic resection rectopexy) (Table 3). Based on
these data, we assume a recurrence rate 2 years after
randomization of 20% for the Delorme’s procedure and
5% for resection rectopexy, respectively. If the unstrati-
fied two-sided log rank test at level of significance α=5%
was applied 2 x 50=100 patients would be required to
achieve a power of 1 - beta=80% (nQueryAdvisorR 7.0,
[29]). It is expected that the rate of loss to follow-up
without recurrence of full-thickness rectal prolapse will
add up to 30%. Even though the lack of information on
the primary endpoint at 2 years for these patients is
partly addressed by the applied time-to-event method,
another 30% of patients will be randomized to compen-
sate for this partial loss of information. It can be
expected that application of the center-stratified version
Table 2 Definitions of secondary outcomes
Surgical complications
Postoperative ileus Obstructive or paralytic symptoms after surgery with the need to suspend food
intake and/or insert a gastric tube; this has to be confirmed radiologically (by abdominal sonography
or plain abdominal X-ray or CT scan)
Postoperative hemorrhage Need for administration of two or more red cell concentrates within the first 24 h postoperatively
or need for reoperation
Surgical site infection CDC definition [21]
Intra-abdominal abscess Intra-abdominal collection of purulent or infected fluid (confirmed by culture) confirmed by
puncture or by surgical reintervention
Anastomotic leakage Grade A-C, Definition of grade according to International Study Group of Rectal Cancer 2010,
diagnosed by CT scan with radiographic enema, endoscopy, drain secretion (stool) or reoperation
Non-surgical complications
Thrombosis Clinical evidence (for example, pain, swelling, warmth, erythema) of a leg or pelvic vein thrombosis
confirmed by duplex sonography or CT angiography, which was not previously known
Pulmonary embolism Clinical (for example, tachycardia, dyspnea) and/or radiological evidence of pulmonary embolism
confirmed by spiral CT or lung perfusion scintigram
Postoperative pulmonary infection At least three of the following:
- temperature > 38°C
- purulent tracheal secretion
- leucocytes >12 or < 4.5 [10E9/L]
- elevated CRP
AND Evidence for pulmonary infection radiologically
Renal failure Need for dialysis or hemofiltration
Cerebral insult Ischemic or non-ischemic cerebrovascular event with persistent paresis or paralysis without previous
history confirmed by CT or MRT
Myocardial infarction Electrocardiogram (NSTEMI or STEMI) and enzyme (Troponin I) changes suggestive of myocardial
infarction or needing admission to coronary care unit
Serious adverse events SAE occurring from the day of randomization until regular end of trial follow-up or withdrawal
Mortality All causes of mortality within 3 months after primary surgery
Duration of surgical
intervention
First incision to the completion of skin closure (resection rectopexy) or the last coloanal suture
(Delorme’s procedure)
Length of initial hospital stay Means the hospitalization period from the primary operation date until the day of discharge
(= postoperative hospital stay)
Reoperation rate for recurrent prolapse Any surgical intervention for a recurrence
Cumulative hospital stay Defined by the days in hospital after the primary surgery as well as the following hospitalizations
due to complications or recurrence within 24 months after the primary operation
Change of quality of life, constipation and incontinence
Measured by means of the appropriate questionnaires SF-12, ([22], validated in German),
Herold constipation score ([23], evaluated in German, but not yet published), Wexner-Score ([10],
non-validated in German, most commonly used score) and Rockwood-FIQLScore ([24], validated),
prior to the surgical intervention as well as 6, 12, and 24 months after the intervention
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Based on these considerations, a total of 130 patients
(2 x 65 patients) will be allocated to the trial which
should be sufficient to assure a power of 80% for the
confirmatory analysis.
Analysis
The allocation of all patients to the different analysis
populations will be defined prior to the analysis (full
analysis set (FAS) according to the intention-to-treat
principle (ITT; all randomized patients as randomized),per protocol (PP) analysis set, safety analysis set). The
procedure of allocation will be documented in the statis-
tical analysis plan. During the data review, deviations
from the protocol will be assessed as ‘minor’ or ‘major’.
Major deviations from the protocol will lead to the ex-
clusion of a patient from the PP analysis set.
The confirmatory analysis is performed for the full
analysis set. The null-hypothesis ‘no difference in the
time to recurrence of full-thickness rectal prolapse be-
tween experimental and control intervention during the
2-year follow-up after randomization’ is tested by
Table 3 Literature review for sample size calculation
Delorme’s procedure








Senapati (1994) 32 (8/24) Retrospective 12.5 41 16
Oliver (1994) 40 (5/35) Retrospective 22 68 n.s.
Tobin (1994) 49 (6/43) Prospective 26 50 n.s.
Lechaux (1995) 85 (8/77) Retrospective 13.5 69 n.s.
Pescatori (1998) 33 Retrospective 21 n.s. n.s.
Watts (2000) 101 (10/91) Retrospective 30 89 44
Watkins (2003) 52 (6/46) Retrospective 10 58 n.s.
Tsunoda (2003) 31 (7/24) Retrospective 13 63 38
Marchal (2005) 60 (7/53) Retrospective 23 42 54
(Laparoscopic) Resection rectopexy








Huber (1995) 42 (2/40) Prospective 0 65 41
Stevenson (1998) 30 (1/29) Prospective 0 70 64
Bruch (1999) 72 (4/68) Prospective 0 64 76
Kim (1999) 176 (16/160) Retrospective 5 55 43
Kellokumpu (2000) 34 (3/31) Prospective 7 n.s. 67
Carpelan (2005) 75 (11/64) Retrospective 3 n.s. n.s.
Ashari (2005) 117 (1/116) Prospective 2.5 62 69
Kariv (2005) 111 (14/97) Prospective 11 n.s. n.s.
n.s., Not specified.
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two-sided level α=5%. Drop-out and lost-to-follow-up
without recurrence of full-thickness rectal prolapse are
considered as censoring events.
For the analysis of the secondary outcomes descriptive
methods will be used, including the calculation of appro-
priate summary methods for the empirical distribution as
well as calculation of descriptive two-sided P values for
comparisons of treatment groups. A special focus of the
exploratory analyses will be on the time course of the pri-
mary as well as the secondary endpoints. Additionally, sen-
sitivity analyses will be conducted for different study
populations (per protocol population, appropriate sub-
groups). Further exploratory analyses will be performed to
identify potential prognostic factors for the intervention ef-
fect. The time to recurrence of full-thickness rectal
prolapse will additionally be analyzed applying a Cox
regression model that includes covariates of potential prog-
nostic value.
The safety analysis is based on all randomized patients
who were treated with the interventions under investiga-
tion. The analysis includes calculation and comparison
of the rates of specified complications (see secondary
endpoints) and serious adverse events as well as of se-
verity and relationship to intervention and graphicaldisplay of the time course. Furthermore, statistical meth-
ods are used to assess the quality of data and the homo-
geneity of intervention groups.
All analyses will be done using SAS version 9.1 or
higher.
Withdrawals
Participants are allowed to withdraw their written
informed consent for the trial at any time and without giv-
ing reasons for their decision. If investigators or members
of the independent Data Monitoring and Safety Board raise
any concerns on an individual patient’s safety, the patient
will be withdrawn from the trial.
Stopping guidelines
The surgical interventions applied in this trial are clinic-
ally established standard methods for the treatment of
rectal prolapse. Therefore, SAEs that will cause a prema-
ture end of the trial are not anticipated.
The DSMB will be informed about the recruitment
and relevant safety data in regular time intervals. If any
safety concerns arise, the DSMB members will confer on
the continuation of the trial and can recommend stop-
ping of the trial. The Ethic Committees then have to be
informed.
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Funding
DeloRes is funded by the German Research Foundation
(Deutsche Forschungsgemeinschaft, DFG).
Monitoring
Clinical monitoring will be performed by an institution
which is independent from other trial staff and experi-
enced due to participation in many other surgical trials.
Monitoring procedures will be adapted to the study spe-
cific risks for the patients and standard operating proce-
dures (SOP) will be implemented to ensure patients safety
and integrity of the clinical data, for example, primary
endpoint in adherence to study protocol. Pre-study visits
will be performed in centers interested in participating in
the study in order to ensure high compliance quality of
the participating centers concerning, for example, patient
recruitment and documentation. Prior to study start, all
participating centers will be personally trained and intro-
duced into all study specific procedures during individual
on site initiation visits. Regular on-site monitoring visits
are planned at all sites depending on the recruitment rate
and quality of the data (approximately one visit per site
and year). The investigator must allow the monitor to look
at all essential documents and must provide support at all
times to the monitor. For all subjects clinical source data
verification (SDV) for all clinical items is planned. The ex-
tent of further SDV and/or the frequency of monitoring-
visits will be adapted for individual centers in case of bad
quality of data or if common protocol violations are
observed. In return, frequency of monitoring visits can be
reduced for reliable and compliant centers with high data
quality. In addition to the SOPs all procedures will be pre-
defined in a study-specific monitoring manual. Queries
(for example, in case of missing values, implausibility, et
cetera) have to be answered by the investigators in a timely
manner in order to avoid that errors in data capture or
entry are held on to.
Data and safety monitoring board (DSMB)
To enable an independent risk assessment for the differ-
ent surgical procedures, potentially related serious ad-
verse events will be noted and periodically assessed by
the independent Data and Safety Monitoring Board
(DSMB). Detailed working procedures are defined in a
different document.
Steering committee
An independent steering committee will be established.
The steering committee will supervise the conduct of
the trial and will issue recommendations for early ter-
mination, modifications or continuation of the trial, if
necessary. The steering committee must be informed in
a timely manner of SAE.Ethical and legal aspects
Before the start of the trial, the trial protocol, informed
consent document, and any other trial documents were
submitted to the independent ethics committee.
The realization of this trial is ethically justifiable since
both surgical techniques are routinely used. Study-
specific medical interventions exceeding this routine are
not planned. Regarding the benefit/risk ratio of this trial
for patients, no ethical objections for the realization
should exist.
The procedures set out in the trial protocol, pertaining
to the conduct, evaluation, and documentation of this
trial, are designed to ensure that all persons involved in
the trial abide by Good Clinical Practice (GCP) and the
ethical principles described in the current revision of the
Declaration of Helsinki. The trial will be carried out in
keeping with local legal and regulatory requirements.
Benefit-risk assessment
Benefit-risk assessment will be critically reviewed and
has to be approved by the ethics committees in advance
before first recruitment.
All interventions applied in this trial represent clinic-
ally established, standard methods of treating full-
thickness rectal prolapse. Therefore the applicants do
not anticipate any serious adverse event that might be
triggered due to the patient’s participation in the trial
itself.
Discussion
An evidence-based optimal surgical treatment for all
patients with rectal prolapse does not exist [30]. Currently,
there is no valid evidence as no conclusive data are yet
available from larger randomized or even adequately case-
controlled studies. Perineal approaches, such as the
Delorme’s procedure, are deemed less invasive compared
to abdominal procedures. Further advantages are shorter
intervention time and the possibility to perform the oper-
ation under spinal or epidural anesthesia. On the other
hand, the recurrence rates after such an approach are
thought to be significantly higher than after an abdominal
approach.
A prospectively randomized, adequately powered trial
comparing these two established operation techniques
with prolapse recurrence as primary outcome has never
been successfully completed. In addition, trial registers
of ongoing prospective studies do not indicate that there
currently is a recruiting trial investigating this question
(last search October 7, 2011).
An updated Cochrane review of Tou et al. [18] could
only include one RCT comparing a perineal to an abdom-
inal approach in a single center setting with a sample size
of 20 and a median follow-up period of 17 months. In this
study only one recurrence occurred in the perineal group
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trials with adequate statistical power, long-term follow-up,
and quality of life assessment is concluded by the authors
and reference is made to the PROSPER Trial still ongoing
at the time of the Cochrane review update.
The so-called PROSPER Trial in the United Kingdom
[32] compared abdominal to perineal surgical approaches
for rectal prolapse in a pragmatic two-stage randomization
trial design depending on the surgeons degree of uncer-
tainty which of four approaches to choose. The study was
able to recruit 293 patients from 33 centers over a 7-year
period from February 2001 up to the cessation of the trial
in August 2008, but only 26 patients were actually rando-
mized to one of the two approaches (last available
newsletter from December 2005, see trial website). All
other patients were allocated to one of the two procedures
by surgeon’s preference. In view of the very small number
of patients actually randomized to a perineal versus an ab-
dominal approach, the conclusions of this study are going
to be very limited and the risk of selection bias is high. In
addition, the majority of recruiting centers recruited less
than 10 patients to the study, further reducing the validity
of the results.
Considering the lessons learned from the PROSPER
Trial, an urgent need currently exists for an adequately
powered, simple parallel-group randomized trial compar-
ing the abdominal to the perineal approach in rectal pro-
lapse. Contrarily to the PROSPER Trial, clinical equipoise
regarding the two surgical approaches has been concluded
after extensive discussion of the available data as the con-
fidence intervals of the published studies on the two
approaches overlap considerably. Even if the study shows
that the abdominal procedure results in significantly less
recurrences this may be outweighed by a considerably
higher morbidity and possibly less improved quality of life.
This trial therefore only allows randomization to a peri-
neal or abdominal approach. A loss of eligible patients to
an observational non-randomized arm, as was the case for
the majority of patients in the PROSPER Trial, will not be
possible.
This trial is designed as an expertise-based trial aiming
at strong internal validity by high performance and
standardization. Generalizability may be reduced by the
expertise-based trial design. However, this type of sur-
gery in larger numbers is predominantly performed by
specialized surgeons. For these surgeons but also for
general surgeons operating only on a few cases per year
the results of this trial should have an important impact
on clinical practice by determining the most effective
treatment for rectal prolapse.
In summary, considering the scarce high-level evi-
dence available up to date we hope that our trial will
add the necessary and confirmatory data to analyze
which surgical approach is indeed superior.Trial status
Recruitment is running since September 2010. All study
centers have been initiated. As of March 2012, 186 patients
have been screened. As of June 2012, 34 patients have been
randomized.
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